Aurobindo Pharma’s wholly owned step-down subsidiary, Agile Pharma BV, has incorporated a new wholly owned subsidiary in France named Arrow Pharma Production SAS. The new entity was established on 21 May 2026, as per a recent disclosure.
Arrow Pharma Production SAS will focus on the manufacturing of generic formulations, expanding Aurobindo Pharma‘s reach in the European pharmaceutical market. The incorporation of this subsidiary is part of Aurobindo Pharma’s strategic initiative to enhance its manufacturing capabilities and product offerings in the region.
Agile Pharma BV, based in the Netherlands, is the holding company of the newly formed Arrow Pharma Production SAS. As a wholly owned step-down subsidiary of Aurobindo Pharma, Agile Pharma’s new venture will also be a wholly owned step-down subsidiary of the listed Indian entity.
The incorporation of Arrow Pharma Production SAS did not require any governmental or regulatory approvals. The company has an authorised capital of 100,000 EUR, which has been fully subscribed in cash, with 100,000 shares valued at 1 EUR each.
Aurobindo Pharma’s expansion into France through Arrow Pharma Production SAS underscores its commitment to strengthening its presence in the generic formulations sector across Europe.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).